← Human Trials & Peer-Reviewed Studies
Systemic and renal effects of an ET(A) receptor subtype-specific antagonist in healthy subjects.
Plain-language guide to PMID 9692778 (1998): double-blind randomized controlled trial of Peptides, Cyclic in 10 subjects.
Key Facts
- PMID
- 9692778
- Journal
- British journal of pharmacology
- Year
- 1998
- Study type
- Randomized Controlled Trial
- Authors
- Schmetterer L et al. (6 authors)
- DOI
- 10.1038/sj.bjp.0701923
What This Study Did, in Plain Language
What Was Tested
Researchers studied Peptides, Cyclic in this randomized controlled trial publication.
The aim of the present study was to characterize the effects of BQ-123, a specific ET(A) receptor antagonist on systemic and renal haemodynamics in healthy subjects.
Why It Was Studied
Endothelins (ETs) might play a pathophysiological role in a variety of vascular diseases.
This was done at baseline and during infusion of exogenous ET-1. 2.
Who Took Part
According to the abstract, 10 subjects were involved.
By PubMed's age tags, the people studied were adults, men only.
How the Study Was Run
In design terms this was a randomized, double-blind, placebo-controlled and crossover study.
Random assignment meant chance, not the researchers, decided who got Peptides, Cyclic and who got the comparison, which limits bias.
As a double-blind Peptides, Cyclic study, the assignments were hidden from both participants and investigators until the end.
The comparison arm used a placebo, so changes seen with Peptides, Cyclic could be set against what happens without it.
In the crossover set-up each of the subjects took both Peptides, Cyclic and the comparison in turn, acting as their own control.
Renal plasma flow (RPF) and glomerular filtration rate (GFR) were assessed by the para-aminohippurate (PAH) and the inulin plasma clearance method, respectively. 3.
What Was Measured
The subject headings attached to it are Blood Pressure, Endothelin Receptor Antagonists, Endothelin-1, Glomerular Filtration Rate, Hemodynamics, Peptides, Cyclic and Pulse.
What This Means in Plain Language
The paper is a randomized, double-blind and placebo-controlled study of Peptides, Cyclic in 10 subjects.
With fewer than 40 people, it is a small study, so it is better read as an early signal for further research than as a settled answer.
The publication is from 1998 (British journal of pharmacology), a journal based in England.
More context: all human trials.
Related Pages
Source: PubMed record. This explanation is written by PeptideWhiz from the public record. For research and education only. Not medical advice; no dosing information is given.